Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Air Methods emerges from chapter 11
We advised the ad hoc group that negotiated and backstopped the restructuring
HighTide Therapeutics HK$194.1 million IPO
We advised HighTide Therapeutics on its IPO and HKEX listing
GSK exclusive license agreement for HS-20093 with Hansoh Pharma
We advised GSK on the transaction
Auna exchange offer and consent solicitations
We advised the Auna on the transaction
Merit Medical Systems $747.5 million convertible senior notes offering
The 3% convertible senior notes are due 2029
Evolent Health $402.5 million convertible notes offering
The convertible notes are due 2029
Innovent Biologics HK$2.4 billion placement of shares
The shares are listed on the Hong Kong Stock Exchange
Option Care Health $400 million revolving credit facility
We advised the administrative agent, joint lead arranger and joint bookrunner on the facility
Atara Biotherapeutics $100 million at-the-market offering
The stock is listed on Nasdaq